News
Statement for Meeting with Heads of Agencies/High level representatives, 13.6.2017
Heads of Agencies (or agencies with HTA responsibility), from Countries included in EUnetHTA Executive Board (morning session) On June 13, 2017, in a meeting facilitated
Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Final project plan for pharma JA Regorafenib (Stivarga©) This is the final project plan of the pharma JA on Regorafenib (Stivarga©) indicated as monotherapy for
Meeting with Heads of Agencies/High-Level Representatives and Heads of European Pharmaceutical Companies
On 13 June, in a meeting facilitated by the EUnetHTA Directorate and supported by DG SANTE, European stakeholders of Health Technology Assessments (focus pharmaceuticals) came
Press Release: EMA and EUnetHTA step up interaction to align data requirements
A new joint platform for parallel consultation will provide advice to medicine developers and facilitate access to medicines for patients The European Medicines Agency (EMA)
WP4 OTCA02 on “Antibacterial-coated Sutures Versus Non-Antibacterial-Coated Sutures for the Prevention of Abdominal, Superficial and Deep Incisional, Surgical Site Infection (SSI)” is now available.
We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL
WP4 OTCA05 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is now available.
We are pleased to announce that the CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is available. The purpose of
Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small
Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
This is the final project plan of the Other Technologies CA on Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk. (FINAL) Project
The CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is now available.
We are pleased to announce that the CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is available. The purpose of
The CA of JA3 WP4 on “Antibacterial-coated Sutures Versus Non-Antibacterial-Coated Sutures for the Prevention of Abdominal, Superficial and Deep Incisional, Surgical Site Infection (SSI)” is now available.
We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL
